Ratifi English Iniciar sesión
Ratifi

Proyectos federales de Congress.gov. Proyectos estatales de Open States.

SB 1486Sesión 2025-2026

An Act providing for prohibitions on discriminatory actions by manufacturers or distributors of certain drugs and for reimbursement claims methodology; providing for grants for sexually transmitted disease clinics; imposing duties on the Department of Human Services and Office of Attorney General; and imposing penalties.

Printer's No. PN2028

See other bills
under the
same topic PRINTER'S NO. 2028 THE GENERAL ASSEMBLY OF PENNSYLVANIASENATE BILL No.1486 Session of 2026 INTRODUCED BY BROOKS, OCTOBER 13, 2026 REFERRED TO HEALTH AND HUMAN SERVICES, OCTOBER 13, 2026 AN ACTProviding for prohibitions on discriminatory actions by manufacturers or distributors of certain drugs and for reimbursement claims methodology; providing for grants for sexually transmitted disease clinics; imposing duties on the Department of Human Services and Office of Attorney General; and imposing penalties.The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows:Section 1. Short title.This act shall be known and may be cited as the 340B Contract Pharmacy Protection Act.Section 2. Definitions.The following words and phrases when used in this act shall have the meanings given to them in this section unless the context clearly indicates otherwise:"340B drug." A drug that a covered entity may purchase at a reduced price under 42 U.S.C. § 256b (relating to limitation on prices of drugs purchased by covered entities)."Contract pharmacy." A pharmacy that is contracted by a covered entity to provide services to and on behalf of the 1234567891011121314151617181920 covered entity with respect to 340B drugs purchased by the covered entity."Covered entity." The following:(1) As defined in section 340B(a)(4) of the Public Health Service Act participating or authorized to participate in the program described in section 340B of the Public Health Service Act.(2) For purposes of this definition, a family planning project receiving a grant or contract under section 300 of the Public Health Service Act shall be operating in compliance with section 1008 of the Public Health Service Act and regulations promulgated thereunder."Covered insurer." The following:(1) A Medicaid managed care organization or entity that reimburses covered entities or contract pharmacies for prescription drugs or dispensing services on behalf of patients, including an entity that holds a valid license by the Insurance Department with accident and health authority to issue a health insurance policy and governed under any of the following:(i) The act of May 17, 1921 (P.L.682, No.284), known as The Insurance Company Law of 1921, including section 630 and Article XXIV of that act.(ii) The act of December 29, 1972 (P.L.1701, No.364), known as the Health Maintenance Organization Act.(iii) 40 Pa.C.S. Ch. 61 (relating to hospital plan corporations) or 63 (relating to professional health services plan corporations).(2) The term does not include a medical assistance fee-20260SB1486PN2028 - 2 - 123456789101112131415161718192021222324252627282930 for-service program under Article IV of the act of June 13, 1967 (P.L.31, No.21), known as the Human Services Code, an individual paying for drugs on the individual's own behalf or on behalf of another individual, the Pennsylvania Employees Benefit Trust Fund or any successor organization that only provides prescription drug benefits for employees of the Commonwealth and their covered dependents or the Special Pharmaceuticals Benefits Program operated by the department."Department." The Department of Human Services of the Commonwealth."Manufacturer." An entity defined under section 1927(k) of the Social Security Act (42 U.S.C. § 1396r-8(k))."Pharmacy benefit manager." A person, business or other entity that performs pharmacy benefit management for covered insurers."Public Health Service Act." The Public Health Service Act (58 Stat. 682, 42 U.S.C. § 201 et seq.)."Third-party logistics provider." As defined under 21 U.S.C. § 360eee(22) (relating to definitions)."Wholesale distributor of prescription drugs." A wholesale distributor of prescription drugs as defined under the act of December 14, 1992 (P.L.1116, No.145), known as the Wholesale Prescription Drug Distributors License Act.Section 3. Prohibition of certain discriminatory actions by a manufacturer or distributor.(a) Prohibition.--A manufacturer, an agent or affiliate of a manufacturer, or distributor or third-party logistics provider of a manufacturer's drugs, may not, directly or indirectly, deny, restrict, prohibit or otherwise interfere with the acquisition of a 340B drug by, or delivery of a 340B drug to, a 20260SB1486PN2028 - 3 - 123456789101112131415161718192021222324252627282930 location authorized by a covered entity to receive the 340B drug, unless receipt of the 340B drug is prohibited by Federal law.(b) Claims and utilization data.--A manufacturer, an agent or affiliate of a manufacturer, or distributor or third-party logistics provider may not, either directly or indirectly, require a covered entity to submit claims or utilization data as a condition for allowing the acquisition of a 340B drug by, or delivery of a 340B drug to, a covered entity unless the claims or utilization data sharing is required by Federal law.Section 4. Reimbursement claims methodology.The department, covered insurer, pharmacy benefit manager or any other entity that administers or manages prescription drug benefits on behalf of the department or a managed care organization, shall rely exclusively on a claims-level methodology involving the use of a nationally recognized billing modifier for identifying drugs purchased under section 340B of the Public Health Service Act when paying for drugs on behalf of Medicaid to ensure that claims for the drugs are removed from the encounter data required under section 1903(m)(2)(A)(xiii) of the Social Security Act (Public Law 74-271, 42 U.S.C. § 1396b(m)(2)(A)(xiii)) and excluded from Medicaid drug rebate requests.Section 5. Sexually transmitted disease clinics.The department shall ensure that:(1) no later than 90 days after the effective date of this paragraph, each sexually transmitted disease clinic shall receive a grant of at least $500 from the department's Federal funding under section 318 of the Public Health Service Act to perform sexually transmitted disease testing and treatment; and20260SB1486PN2028 - 4 - 123456789101112131415161718192021222324252627282930 (2) all new awards or renewals provided to sexually transmitted disease clinics shall provide for a grant of at least $500 from the department's Federal funding under section 318 of the Public Health Service Act to perform sexually transmitted disease testing and treatment.Section 6. Penalties.(a) Enforcement.--The commission of any act that violates section 3 shall constitute an unlawful practice within the meaning of the act of December 17, 1968 (P.L.1224, No.387), known as the Unfair Trade Practices and Consumer Protection Law. The Office of Attorney General shall have jurisdiction, consistent with the provisions of the Unfair Trade Practices and Consumer Protection Law, to enforce the provisions of section 3 and to promulgate regulations implementing the provisions of section 3.(b) Fines.--The Office of Attorney General shall impose, upon written notice, a fine on a manufacturer, wholesale distributor of prescription drugs, third-party logistics provider, or an agent or affiliate of the manufacturer, wholesale distributor of prescription drugs or third party logistics provider, that violates section 3, in an amount of $50,000 per each violation. Each package of 340B drugs determined to be subject to a prohibited act under section 3 shall constitute a separate violation under section 3.(c) Suspension.--The Office of Attorney General shall suspend the ability of a manufacturer, wholesale distributor of prescription drugs, third-party logistics provider, or an agent or affiliate of a manufacturer, wholesale distributor of prescription drugs or third-party logistics provider, to conduct business in this Commonwealth if a violation under section 3 is 20260SB1486PN2028 - 5 - 123456789101112131415161718192021222324252627282930 not rectified within 30 days of the date when the written notice is sent to the manufacturer, wholesale distributor of prescription drugs, third-party logistics provider, or an agent or affiliate of the manufacturer, wholesale distributor of prescription drugs or third-party logistics provider under section 3(b).(d) Injunctive relief.--A covered entity or contract pharmacy may immediately seek injunctive relief in Commonwealth Court to enforce the provisions of this act.Section 7. Federal preemption.Nothing in this act shall be construed or applied to be in conflict with Federal law and related regulations, including 21 U.S.C. § 355-1 (relating to risk evaluation and mitigation strategies), or other laws of this State, if the State law is compatible with applicable Federal law.Section 8. Effective date.This act shall take effect immediately.20260SB1486PN2028 - 6 - 1234567891011121314151617

Texto oficial de la Legislatura de Pennsylvania. El formato se adaptó para leerlo en Ratifi.